Since 2008 new drugs have been introduced, namely the non-vitamin K antagonist oral anticoagulants (also called new oral anticoagulants or NOACs) and the antiplatelets prasugrel and ticagrelor. "We ... News Medical: Study: Non-vitamin K antagonist oral anticoagulants linked to reduced kidney risks Medical Xpress: ESC recommends uninterrupted vitamin K antagonists during ablation and device implantation Medscape: Comparison of Idraparinux With Vitamin K Antagonists for Prevention of Thromboembolism in Patients With Atrial Fibrillation Comparison of Idraparinux With Vitamin K Antagonists for Prevention of Thromboembolism in Patients With Atrial Fibrillation Healio: INVICTUS trial supports vitamin K antagonists for rheumatic heart disease-associated AF Experts have recommended uninterrupted anticoagulation with vitamin K antagonists during ablation and device implantation.
Dramatic changes in the field during the last five years demanded a revision, ... The New England Journal of Medicine: Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied. We ... Nasdaq: Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress Healio: Vitamin K antagonist monotherapy reduces risk for first-time MI, stroke in AF Please provide your email address to receive an email when new articles are posted on .
vitamin k antagonist drugs, Patients with atrial fibrillation undergoing vitamin K antagonist monotherapy have a lower risk for first-time ... Vitamin K antagonist monotherapy reduces risk for first-time MI, stroke in AF Healio: Non-vitamin K antagonist oral anticoagulants beneficial for patients with AF, cancer Please provide your email address to receive an email when new articles are posted on . In patients with atrial fibrillation and cancer, non-vitamin K antagonist oral anticoagulants outperformed ... Researchers conducted a retrospective cohort study using data from linked registers to evaluate whether treatment with vitamin K antagonists vs direct oral anticoagulants was associated with the ... In a randomized trial involving patients who had atrial fibrillation after TAVR, edoxaban was noninferior to vitamin K antagonists with respect to a composite outcome of death, MI, stroke, ...
vitamin k antagonist drugs, TCTMD: Direct Oral Anticoagulants Versus Vitamin K Antagonists in Atrial Fibrillation Patients With Bioprosthetic Valves: A Systematic Review, Meta-Analysis and Network Meta-Analysis Direct Oral Anticoagulants Versus Vitamin K Antagonists in Atrial Fibrillation Patients With Bioprosthetic Valves: A Systematic Review, Meta-Analysis and Network Meta-Analysis EurekAlert!: Protein induced by vitamin K absence or antagonist II in primary liver cancer: Basic research insights and clinical applications Protein induced by vitamin K absence or antagonist II in primary liver cancer: Basic research insights and clinical applications
